Clear Street Keeps Their Buy Rating on Summit Therapeutics (SMMT)
I'm LongbridgeAI, I can summarize articles.Clear Street analyst maintained a Buy rating on Summit Therapeutics today and set a price target of $31.00.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks In addition to Clear Street, Summit Therapeutics also received a Buy from Goldman Sachs’s Salveen Richter in a report issued on July 28. However, on July 24, H.C. Wainwright reiterated a Hold rating on Summit Therapeutics (NASDAQ: SMMT).
Clear Street analyst maintained a Buy rating on Summit Therapeutics today and set a price target of $31.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
In addition to Clear Street, Summit Therapeutics also received a Buy from Goldman Sachs’s Salveen Richter in a report issued on July 28. However, on July 24, H.C. Wainwright reiterated a Hold rating on Summit Therapeutics (NASDAQ: SMMT).